Research programme: RNA interference-based therapeutics - Alnylam/Merck

Drug Profile

Research programme: RNA interference-based therapeutics - Alnylam/Merck

Alternative Names: RNAis - Alnylam/Merck

Latest Information Update: 27 Sep 2007

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Merck & Co
  • Class
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Spinal cord injuries; Unspecified

Most Recent Events

  • 27 Sep 2007 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
  • 27 Sep 2007 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 20 Sep 2007 Alnylam Pharmaceuticals and Merck & Co have mutually agreed to terminate their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top